Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The unique ORS effervescent tablet has been developed according to the latest guidelines of the WHO. It has a substantial marketshare in several countries. We are looking for partners to further expand this success. More
Our client company has developed an innovative frozen lozenge technology designed to deliver pharmaceuticals and OTC products, which offers a new alternative administration method for paediatric and otherwise difficult to swallow therapeutics. More
The development of a transdermal therapeutic system offers the advantages of constant plasma levels i.e. avoiding of plasma peaks and providing of therapeutic plasma level during the early morning hours More
Adhesive patch containing and delivering essential and balsamic oils for the symptomatic treatment of the common cold and nasal congestion More
Multilayered controlled release oral solid pharmaceutical composition in tablet form suitable for oral administration comprising at least two layers containing active material in association with excipients and additives. More
Prevents oral trauma to surgical or long term ventilated patients due to insertion of endotracheal tube; additionally this novel device is beneficial in endoscope labs for both bronchoscope and transesophageal echocardiogram (TEE) procedures. More
Method of Measuring by Gas Dilution Residual Lung Volume in Infants More
Researchers at the School of Pharmacy, University of London, have developed a novel method for formulation of drugs for efficient delivery to the lung using pressurized metered dose inhalers (pMDIs). More
NexACT(R) utilizes highly effective, novel excipients or “penetration enhancers” to dramatically improve absorption and bioavailability of drugs. Varying the concentration of the enhancer allows for local or systemic delivery of drug, as desired. More
Infant Lung Function - Quantitative Measurement More
Related Reports
Market Research Reports provided by reports.innovaro.com
Nov 2010 - 178 pages - $1,495
Nov 2010 - 160 pages - $1,495
Jun 2006 - 492 pages - $2,495
Mar 2011 - 28 pages - $500
Jan 2011 - 33 pages - $500
Jan 2011 - 22 pages - $500
Oct 2011 - 60 pages - $500
Jun 2011 - 34 pages - $500
Oct 2011 - 30 pages - $500
Apr 2010 - 510 pages - $2,695
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Adult respiratory distress syndrome
- Allergy, respiratory
- Asthma
- Asthma, bronchospasm
- Bronchitis
- Chest disorder (other)
- Chlamydia pneumoniae
- Chronic obstructive pulmonary disease
- Cough
- Cystic fibrosis
- Dysplasia, bronchopulmonary
- Emphysema
- Granulomatous lung disease sarcoidosis
- Idiopathic respiratory distress syndrome
- Meconium aspiration syndrome
- Nasal disorder (other)
- Obstructive airway disease
- Pneumonia
- Pneumonocystis carinii lung infection
- Pseudomonas lung infection
- Respiratory disorder (other)
- Respiratory syncytial virus
- Respiratory tract infections
- Rhinitis
- Rhinovirus (common cold)
- Sinusitis
- Sleep apnea
- Throat disorder (other)
- Tuberculosis
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us